Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (8)

2024

  1. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

    Journal of Clinical Medicine, Vol. 13, Núm. 3

2022

  1. The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 6

2021

  1. Engraftment characterization of risk-stratified AML in NSGS mice

    Blood Advances, Vol. 5, Núm. 23, pp. 4842-4854

  2. Impact of bcr-abl1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib

    Journal of Clinical Medicine, Vol. 10, Núm. 14

2020

  1. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

    Journal for immunotherapy of cancer, Vol. 8, Núm. 1

  2. Bone marrow clonogenic myeloid progenitors from NPM1-mutated AML patients do not harbor the NPM1 mutation: Implication for the cell-of-origin of NPM1+ AML

    Genes, Vol. 11, Núm. 1

2019

  1. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis

    Haematologica, Vol. 104, Núm. 2, pp. e54-e58

2017

  1. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

    Stem Cell Reports, Vol. 8, Núm. 6, pp. 1573-1586